Status:
COMPLETED
An Open Study to Investigate the Safety and Efficacy of Optivate® in Haemophilia A Patients Undergoing Surgery.
Lead Sponsor:
Bio Products Laboratory
Conditions:
Haemophilia A
Eligibility:
All Genders
12+ years
Phase:
PHASE3
Brief Summary
The main objective of the study is to investigate the safety and efficacy of Optivate®, administered in appropriate dosage to present bleeding and achieve haemostasis in patients with Haemophilia A un...
Eligibility Criteria
Inclusion
- Diagnosed with Haemophilia A, at least 12 years of age, due to undergo surgery and have a lifetime exposure of at least 20 exposures to a FVIII concentrate.
Exclusion
- \-
Key Trial Info
Start Date :
November 1 2001
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT02250482
Start Date
November 1 2001
Last Update
February 15 2018
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Klinika Haematologii, Akademia Medyczna w Gdansku, ul.
Debinki 7, 80-211 Gdansk, Poland
2
Klinika Haematologii, Akademia Medyczna w Lublinie, ul.
Dr K Jaczewskiego 8, 20-090, Lublin, Poland
3
Klinika Haematologii, Akademia Medyczna w Poznaniu, ul.
Szkolna 8/12, 61-833 Poznan, Poland
4
Haemophilia Centre, Addenbrooke's Hospital, Hills Road
Cambridge, United Kingdom, CB2 2QQ